Fibrinolysin

Source: Wikipedia, the free encyclopedia.
Fibrinolysin
Clinical data
AHFS/Drugs.comInternational Drug Names
Pregnancy
category
  • C
Routes of
administration
ointment for local application, in combination with deoxyribonuclease
ATC code
Legal status
Legal status
  • Rx only (where available)
ECHA InfoCard
100.029.661 Edit this at Wikidata
Chemical and physical data
Molar mass~ 13,800 g/mol
 ☒NcheckY (what is this?)  (verify)

Fibrinolysin is an enzyme derived from plasma of

Biological Unit
) fibrinolysin and 666 BUs desoxyribonuclease per gram.

Fibrinolysin attacks and inactivates

tissue
. According to the manufacturer the ointment provides enhanced wound cleaning and accelerates the healing process.

Both enzymes are marginally resorbed into systemic circulation because of their very high molecular weight and their macromolecular structure.

The activity of both enzymes is almost completely exhausted after 24 hours. Usually, it is necessary to repeat the application (and renew the dressing) every 6 to 8 hours until healing becomes complete.

The ointment is marketed by Pfizer under the brand name Fibrolan in a variety of countries (e.g. Switzerland). It is currently not approved in the USA.

Where approved, Fibrolan has been licensed on the basis of claimed good therapeutical experience, but adequate and well controlled studies are still lacking.

In the past, combinations with the antibiotic chloramphenicol were available, but because chloramphenicol in any form of application has led to aplastic anemia and death, these were banned. Additionally, combinations with the antifibrinolytic agent tranexamic acid have been withdrawn from pharmaceutic markets.

Indications

Enzymatic wound cleaning to assist healing of minor burns, superficial wounds,

ulcus cruris, and superficial hematoma
.

Contraindications and Precautions

The ointment should not be used in patients with a known hypersensitivity to any ingredient. It should be used with caution in patients with hypersensitivity to bovine proteins in general and in pregnant women (category C), because no human data is available.

Side-Effects

Infrequently, local reactions such as increased pain or a stitching/burning sensation are noticed. No systemic anticoagulant activity has been seen due to the exclusively local character of treatment.

Interactions

Not known.

See also

External links

  • Swiss scientific product information
  • Birk Y, Khalef S, Jibson MD (September 1983). "Purification and properties of protease F, a bacterial enzyme with chymotrypsin and elastase specificities". Arch. Biochem. Biophys. 225 (2): 451–7.
    PMID 6226244
    .